



Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27866/36470A	Serial No. 09/976,935
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Applicant Donald E. Staunton	
		Filing Date 10/12/01	Group 1646

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation
							Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>JB</i>		Xiong <i>et al.</i> , "An Isoleucine-based Allosteric Switch Controls Affinity and Shape Shifting in Integrin CD11b A-domain," <i>JBC Papers in Press</i> , (October 16, 2000).					
		J. Biol. Chem. Vol. 275 Pages 38762-38767 (2000)					

RECEIVED
FEB 13 2003
TECH CENTER 1600/2900

EXAMINER <i>JB. Brown</i>	DATE CONSIDERED <i>12 September 2001</i>
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27866/36470A	Serial No. 09/976,935
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Applicant Donald E. Staunton	
		Filing Date 10/12/01	Group 1646 /63/

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate

RECEIVED
DEC 10 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation
							Yes No

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
JBS	C61	Jones <i>et al.</i> , "Ligand occupancy of the $\alpha V\beta 3$ integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor I," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 93:2482-2487 (March, 1996)
JBS	C62	Lu <i>et al.</i> , "An isolated, surface-expressed I domain of the integrin $\alpha L\beta 2$ is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 98(5):2387-2392 (February 27, 2001)
JBS	C63	Nolte <i>et al.</i> , "Crystal structure of the $\alpha 1\beta 1$ integrin I-domain: insights into integrin I-domain function," <i>FEBS Letters</i> , 452:379-385 (1999)

EXAMINER JBS. Bursica	DATE CONSIDERED 2 September 2004
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 1 of 5

RECEIVED

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27866/36470A	Serial No. 09/976,9
INFORMATION DISCLOSURE STATEMENT		Applicant Donald E. Staunton	
		Filing Date 10/12/01	Group 1646 1631

TECH CENTER 1600 2900
AUG 27 2002

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate
JLB	A1	5,847,088	12/08/98	Cousens <i>et al.</i>	530	388.1	
JLB	A2	5,888,809	03/30/99	Allison	435	325	
JLB	A3	6,251,395	06/26/01	Gallatin <i>et al.</i>	424	144.1	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
JLB	C1	Aghazdeh <i>et al.</i> , "Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation," <i>Cell</i> , 102:625-633 (Sept. 1, 2000)
JLB	C2	Amyes <i>et al.</i> , "Trimethoprim-Sensitivity Testing and Thymineless Mutants," <i>J. Med. Microbiol.</i> , 7(2):143-153 (1974)
JLB	C3	Andersen <i>et al.</i> , "Protein export and drug efflux through bacterial channel-tunnels," <i>Curr. Opin. Cell Biol.</i> , 13:412-416 (2001)
JLB	C4	Ausubel <i>et al.</i> , "Enzymatic Amplification of DNA by PCR: Standard Procedures and Optimization," <i>Curr. Protocols Mol. Biol.</i> , 3:15.1.1-15.1.14 (2001)
JLB	C5	Baldock <i>et al.</i> , "A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase," <i>Science</i> , 274:2107-2110 (Dec. 20, 1996)
JLB	C6	Berge <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharmaceutical Sciences</i> , 66(1):1-19 (Jan., 1977)
JLB	C7	Bollag <i>et al.</i> , "Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action" <i>Cancer Research</i> , 55:2325-2333 (June 1, 1995)

EXAMINER JLB. Buser	DATE CONSIDERED 17 September 2004
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



m PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27866/36470A	Serial No. 09/976,993
INFORMATION DISCLOSURE STATEMENT			Applicant Donald E. Staunton	
			Filing Date 10/12/01	Group 1646

1631

AUG 27 2002

RECEIVED

TECH CENTER 1600/2900

JB	C8	Briesewitz <i>et al.</i> , "Expression of Native and Truncated Forms of the Human Integrin α_1 Subunit," <i>J. Biol. Chem.</i> , 268(4):2989-2996 (February 5, 1993)
JB	C9	Chang <i>et al.</i> , "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of α and β T-cell receptor extracellular segments," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 91:11408-11412 (November, 1994)
JB	C10	Copley <i>et al.</i> , "Protein families in multicellular organisms," <i>Curr. Opin. Struct. Biol.</i> , 9:408-415 (1999)
JB	C11	Couzin, "Integrin Crystal Structure Solved," <i>Science</i> , 293:1743-1746 (September 7, 2001)
JB	C12	Cranmer <i>et al.</i> , "Glycoprotein (GP) Ib-IX-transfected Cells Roll on a von Willebrand Factor Matrix under Flow," <i>J. Biol. Chem.</i> , 274(10):6097-6106 (March 5, 1999)
JB	C13	Crompton <i>et al.</i> , "Regulation of Tiam1 Nucleotide Exchange Activity by Pleckstrin Domain Binding Ligands," <i>J. Biol. Chem.</i> , 275(33):25751-25759 (August 18, 2000)
JB	C14	deFougerolles <i>et al.</i> , "Regulation of inflammation by collagen-binding integrins $\alpha 1 \beta 1$ and $\alpha 2 \beta 1$ in models of hypersensitivity and arthritis," <i>J. Clin. Invest.</i> , 105(6):721-729 (March, 2000)
JB	C15	De Vos <i>et al.</i> , "Three-Dimensional Structure of an Oncogene Protein: Catalytic Domain of Human c-H-ras p21," <i>Science</i> , 239:888-893 (February 19, 1988)
JB	C16	Diamond <i>et al.</i> , "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1(CD11b/CD18) for Four Distinct Adhesion Ligands," <i>J. Cell Biology</i> , 120(4):1031-1043 (February, 1993)
JB	C17	Dickeson <i>et al.</i> , "Ligand recognition by the I domain-containing integrins," <i>Cell. Mol. Life Sci.</i> , 54:556-566 (1998)
JB	C18	Didsbury <i>et al.</i> , "rac, a Novel ras-related Family of Proteins That Are Botulinum Toxin Substrates," <i>J. Biol. Chem.</i> , 264(28):16378-16382 (October 5, 1989)
JB	C19	Edwards <i>et al.</i> , "The protein fold of the von Willebrand factor type A domain is predicted to be similar to the open twisted β -sheet flanked by α -helices found in human ras-p21," <i>FEBS Letter</i> , 358:283-286 (1995)
JB	C20	Eliopoulos <i>et al.</i> , "Antimicrobial Combinations," in <i>Antibiotics in Laboratory Medicine</i> , 4 th Ed., pp. 330-396, (V. Lorian, ed., 1996)
JB	C21	Emsley <i>et al.</i> , "Crystal Structure of the I Domain from Integrin $\alpha 2 \beta 1$," <i>J. Biol. Chem.</i> , 272(45):28512-28517 (November 7, 1997)
JB	C22	Emsley <i>et al.</i> , "Structural Basis of Collagen Recognition by Integrin $\alpha 2 \beta 1$," <i>Cell</i> , 101:47-56 (March 31, 2000)

EXAMINER JB. Bures	DATE CONSIDERED 17 September 2001
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	




RECEIVED
AUG 27 2002
SHEET 5 of 5
TECH. CENTER 1600 2900

in PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27866/36470A	Serial No. 09/976,9
INFORMATION DISCLOSURE STATEMENT		Applicant Donald E. Staunton	
		Filing Date 10/12/01	Group 1646 1631

JB	C23	Gibrat <i>et al.</i> , "Surprising similarities in structure comparison," <i>Curr. Opin. Struct. Biol.</i> , 6:377-385 (1996)
JB	C24	Hahn <i>et al.</i> , "The complete sequences of plasmids pFNeo and pMN-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines," <i>Gene</i> , 127:267-268 (1993)
JB	C25	Hardma <i>et al.</i> , eds., "Pharmacokinetics," Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, New York, New York, McGraw-Hill, Chapter 1, pp. 11-16 (1996)
JB	C26	Higuchi <i>et al.</i> , eds., "Prodrug as Novel Drug Delivery Systems, ACS Symposium Series, 14, table of contents only (1975)
JB	C27	Higuchi, "Prodrug and Drug Delivery - An Overview," Bioreversible Carriers in Drug Design Theory and Application, Roche ed., Pergamon Press, Chapter 1, pp. 1-12, (1987)
JB	C28	Hitchings and Baccanari, "Design and Synthesis of Folate Antagonists as Antimicrobial Agents", in <i>Folate Antagonists as Therapeutic Agents</i> , Chapter 4, Vol. 1:151-172 (1984)
JB	C29	Hua Jing <i>et al.</i> , "New structural motifs on the chymotrypsin fold and their potential roles in complement factor B," <i>EMBO J.</i> , 19(2):164-173 (2000)
JB	C30	Huth <i>et al.</i> , "NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(10):5231-5236 (May 9, 2000)
JB	C31	Kirshenbaum <i>et al.</i> , "Predicting allosteric switches in myosins," <i>Protein Science</i> , 8:1806-1815 (1999)
JB	C32	Lee <i>et al.</i> , "Crystal Structure of the A Domain from the α Subunit of Integrin CR3 (CD11b/CD18)," <i>Cell</i> , 80:631-638 (February 24, 1995)
JB	C33	Lochter <i>et al.</i> , " $\alpha 1$ and $\alpha 2$ Integrins Mediate Invasive Activity of Mouse Mammary Carcinoma Cells through Regulation of Stromelysin-1 Expression," <i>Mol. Biol. Cell</i> , 10:271-282 (February, 1999)
JB	C34	Madej <i>et al.</i> , "Threading a Database of Protein Cores," <i>Proteins: Structure, Functions and Genetics</i> , 23:356-369 (1995)
JB	C35	Mandell <i>et al.</i> , "Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections," in <i>The Pharmacological Basis of Therapeutics</i> Chapter 44, Antimicrobial Agents, 1057-1072 (Goodman and Gilman eds., 1996)
JB	C36	Nelson <i>et al.</i> , "Matrix Metalloproteinases: Biologic Activity and Clinical Implications," <i>J. Clin. Oncol.</i> , 18(5):1135-1149 (March, 2000)

EXAMINER JB. Buss	DATE CONSIDERED 17 September 2004
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	



For PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

27866/36470A

Serial No.

09/976835

Applicant

Donald E. Staunton

Filing Date

10/12/01

Group

1646

163/

INFORMATION DISCLOSURE STATEMENT

JB	C37	Nobes, "Rho GTPases and Cell Migration-Fibroblast Wound Healing," <i>Meth. Enzymol.</i> , 325:441-449 (2000)
JB	C38	Nogales <i>et al.</i> , "Tubulin and FtsZ form a distinct family of GTPases," <i>Nature Structural Biology</i> , 5(6):451-458 (June, 1998)
JB	C39	Oxvig <i>et al.</i> , "Conformational changes in tertiary structure near the ligand binding site of an integrin I domain," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 96:2215-2220 (March, 1999)
JB	C40	Pozzi <i>et al.</i> , "Elevated matrix metalloprotease and angiostatin levels in integrin $\alpha 1$ knockout mice cause reduced tumor vascularization," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 97(5):2202-2207 (February 29, 2000)
JB	C41	Ponting <i>et al.</i> , "SMART: identification and annotation of domains from signalling and extracellular protein sequences," <i>Nucl. Acids Res.</i> , 27(1):226-229 (1999)
JB	C42	Poste <i>et al.</i> , "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Vol. XIV, Academic Press, New York, New York, Prescott, ed., Chapter 4, pp. 33-71 (1976)
JB	C43	Qu <i>et al.</i> , "The role of the divalent cation in the structure of the I domain from the CD11a/CD18 integrin," <i>Structure</i> , 4:931-942 (August 15, 1996)
JB	C44	Rich <i>et al.</i> , "Trench-shaped Binding Sites promote Multiple Classes of Interactions between Collagen and the Adherence Receptors, $\alpha_1\beta_1$ Integrin and <i>Staphylococcus aureus</i> Can MSCRAMM," <i>J. Biol. Chem.</i> , 274(35):24906-24913 (August 27, 1999)
JB	C45	Richey <i>et al.</i> , "The Biosynthesis of Folic Acid," <i>J. Biol. Chem.</i> , 244(6):1582-1592 (March 25, 1969)
JB	C46	Rossmann <i>et al.</i> , "Bacterial Expressed DH and DH/PH Domains," <i>Meth. Enzymol.</i> , 325:25-38 (2000)
JB	C47	Rost, "PHD: Predicting One-Dimensional Protein Structure by Profile-Based Neural Networks," <i>Meth. Enzymol.</i> , 266:525-539 (1996)
JB	C48	Sadhu <i>et al.</i> , "LFA-1 Binding Site in ICAM-3 Contains a Conserved Motif and Non-Cotniguous Amino Acids," <i>Cell Adhes. Commun.</i> , 2:429-440 (1994)
JB	C49	Scita <i>et al.</i> , "Signaling from Ras to Rac and beyond: not just a matter of GEFs," <i>EMBO J.</i> , 19(11):2393-2398 (2000)
JB	C50	Schultz <i>et al.</i> , "SMART, a simple modular architecture research tool: Identification of signaling domains," <i>Proc. Nat'l. Acad. Sci. (USA)</i> , 95:5857-5864 (May, 1998)
JB	C51	Schultz <i>et al.</i> , "SMART: a web-based tool for the study of genetically mobile domains," <i>Nucl. Acids Res.</i> , 28(1):231-234 (2000)
JB	C52	Self <i>et al.</i> , "Purification of Recombinant Rho/Rac/G25K from <i>Escherichia coli</i> ," <i>Meth. Enzymol.</i> , 256:3-10 (1995)

EXAMINER

J.B. Brown

DATE CONSIDERED

17 September 2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 5

TECH CENTER 1600/2900

AUG 27 2002

RECEIVED

For m...O-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27866/36470ASerial No.
09/976,6

Applicant

Donald E. Staunton

Filing Date
10/12/01Group
1646
1631

INFORMATION DISCLOSURE STATEMENT

JB	C53	Shi <i>et al.</i> , "Bisubstrate Analogue Inhibitors of 6-Hydroxymethyl-7,8-dihydropterin Pyrophosphokinase: Synthesis and Biochemical and Crystallographic Studies," <i>J. Med. Chem.</i> , 44:1364-1371 (2001)
JB	C54	Symons, "The Rac and Rho pathways as a source of drug targets for Ras-mediated malignancies," <i>Curr. Opin. in Biotech.</i> , 6:668-674 (1995)
JB	C55	John Wiley & Sons, Inc., "Classical Pathway Evaluation," Current Protocols in Immunology, Coligan <i>et al.</i> , eds. Vol. 3, Chapter 13, Unit 13.1 (2000)
JB	C56	Velling <i>et al.</i> , "cDNA Cloning and Chromosomal Localization of Human α_{11} Integrin," <i>J. Biol. Chem.</i> , 274(36):25735-25742 (September 3, 1999)
JB	C57	Worthylake <i>et al.</i> , "Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1," <i>Nature</i> , 408:682-688 (December 7, 2000)
JB	C58	Young <i>et al.</i> , "Predicting conformational switches in proteins," <i>Protein Science</i> , 8:1752-1764 (1999)
JB	C59	Yu <i>et al.</i> , "Ca ²⁺ -mediated GTP-dependent dynamic assembly of bacterial cell division protein FtsZ into asters and polymer networks <i>in vitro</i> ," <i>EMBO J.</i> , 16(17):5455-5463 (1997)
JB	C60	"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, <i>National Committee Clinical Laboratory Standards Guidelines</i> , - 5 th Ed., Vol. 20, No. 2, pp. 1-27, Wayne, PA (January, 2000)

EXAMINER

J.B. Bensen

DATE CONSIDERED

17 September 2004

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.